InvivoChem Cat #:V3700CAS #:857890-39-2 Purity >=98%Description: Lenvatinib (also known as E7080, ER-203492-00) is a multi-targeted, orally bioavailable inhibitor of VEGFR2(KDR)/VEGFR3(Flt-4) for the most part with potential antineoplastic activity. It has IC50 values of 4 nM/5.2 nM for VEGFR2/VEGFR3 respectively, it is less potent against VEGFR1/Flt-1, and is ca.10-fold more selective for VEGFR2/3 against FGFR1, PDGFRalpha/beta in cell-free assays. Lenvatinib is currently undergoing investigation both as monotherapy and in combination with cytotoxic agents for various types of solid tumor, including thyroid carcinoma and hepatocellular carcinoma (in Phase III trials), and melanoma, renal carcinoma, non-small cell lung carcinoma etc.
References: Int J Cancer. 2008 Feb 1; 122(3):664-71; Clin Cancer Res. 2008 Sep 1; 14(17):5459-65.
Related CAS#:417716-92-8 (free base)